| |
| |
|
| Insider
Information: |
Paul Steven M |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,185,025 |
|
|
Indirect Shares
|
632,151 |
|
|
| Direct
Value |
$37,673,864 |
|
|
|
Indirect Value
|
$30,104,525 |
|
|
| Total
Shares |
1,817,176 |
|
|
| Total
Value |
$67,778,389 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eli Lilly & Co |
LLY |
EVP, Science and Techn... |
2010-02-01 |
38,897 |
2010-02-01 |
39,040 |
Premium* |
|
|
Sigma-Aldrich Corp |
SIAL |
Director |
2015-11-18 |
0 |
2007-01-02 |
0 |
Premium* |
|
|
Sage Therapeutics, Inc. |
SAGE |
|
2019-03-21 |
272,777 |
2022-11-28 |
593,111 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2022-04-01 |
1,000 |
2015-01-26 |
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
President and CEO, Dir... |
2016-01-14 |
872,351 |
|
0 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2003-08-05 |
4 |
S |
$64.87 |
$648,716 |
I/I |
(10,000) |
28,877 |
|
- |
|
| LLY |
Eli Lilly & Co |
officerTitle |
• – – |
2006-02-02 |
4 |
S |
$57.00 |
$353,457 |
D/D |
(6,201) |
89,656 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2006-04-21 |
4 |
S |
$52.80 |
$1,320,000 |
D/D |
(25,000) |
64,656 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2006-04-25 |
4 |
S |
$52.06 |
$1,301,507 |
D/D |
(25,000) |
39,656 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2006-10-20 |
4 |
S |
$56.91 |
$275,217 |
I/I |
(4,836) |
1,070 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-02-08 |
4 |
S |
$54.31 |
$548,234 |
D/D |
(10,092) |
54,619 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-02-12 |
4 |
S |
$54.38 |
$396,430 |
I/I |
(7,290) |
8,359 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2008-02-04 |
4 |
S |
$51.49 |
$1,022,881 |
D/D |
(19,822) |
50,300 |
0 |
- |
|
| SAGE |
Sage Therapeutics, Inc. |
|
– • – |
2015-04-01 |
4 |
S |
$48.51 |
$970,200 |
D/D |
(20,000) |
783,650 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2004-09-27 |
4 |
OE |
$14.66 |
$274,095 |
D/D |
18,700 |
39,204 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-10-13 |
4 |
OE |
$23.41 |
$99,997 |
D/D |
4,272 |
21,099 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2005-10-14 |
4 |
OE |
$23.41 |
$461,783 |
D/D |
19,728 |
40,827 |
|
- |
|
| LLY |
Eli Lilly & Co |
officerTitle |
• – – |
2005-12-15 |
4 |
OE |
$34.59 |
$453,475 |
D/D |
13,110 |
90,202 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2006-09-15 |
4 |
OE |
$34.60 |
$99,980 |
D/D |
2,890 |
42,546 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-05-15 |
4 |
OE |
$54.80 |
$109,162 |
D/D |
1,992 |
42,032 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2007-05-21 |
4 |
OE |
$54.80 |
$5,370,838 |
D/D |
98,008 |
138,140 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and Technology |
• – – |
2010-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,249 |
56,249 |
0 |
- |
|
| SIAL |
Sigma-Aldrich Corp |
Director |
– • – |
2014-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
373 |
7,573 |
0 |
- |
|
| SIAL |
Sigma-Aldrich Corp |
Director |
– • – |
2015-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
684 |
8,257 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-02-10 |
4 |
OE |
$14.67 |
$440,100 |
D/D |
30,000 |
31,000 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2020-12-18 |
4 |
OE |
$9.30 |
$139,500 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
Director |
– • – |
2022-04-01 |
4 |
OE |
$11.33 |
$169,950 |
D/D |
15,000 |
16,000 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2024-02-23 |
4 |
OE |
$7.27 |
$599,675 |
D/D |
31,518 |
42,114 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and TechnologyOff |
• – – |
2003-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,504 |
|
- |
|
| LLY |
Eli Lilly & Co |
EVP, Science and TechnologyOff |
• – – |
2003-07-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
42,150 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
